I just found out. Is it too late?

It is not. APOE4 raises lifetime Alzheimer's risk roughly 4–5× above baseline, but it does not seal fate. The members with the largest biomarker swings are the ones who started in their fifties and sixties, every year of intervention bends the curve.

I am joining for a parent, partner, or someone I love.

You belong here too. Most of us started exactly where you are — 88% of members have a family history of Alzheimer's, and for nearly half it was their mother. Caregivers and family members get the same tools, pod, and expert access as every member, alongside people who have walked exactly your road.

I am not a biohacker.

Neither are most members, average member is a 58-year-old woman. The app walks you through every step, your pod keeps you honest, and Dr. Tran is one message away.

I am 3/4, not 4/4. Does this apply?

Yes. Phoenix is built for any APOE4 carrier. The urgency dial is lower, the playbook is the same.

Yes, any time, one click, no questions. 60-day full money-back guarantee on your first quarter.

Trials in South Carolina.

27 APOE4-relevant Alzheimer’s trials run in South Carolina — 12 of them recruiting. Each one translated into plain English, with our read on what it means for an APOE4 carrier.

Where

Charleston · Columbia · Greer · Summerville · Seneca · Fort Mill · Greenville · North Charleston

Recruiting

12 of 27

Built exclusively for APOE 4/4 carriersNCT02565511
A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
This trial tested two investigational drugs, CAD106 (a vaccine-like immunotherapy targeting amyloid) and CNP520 (a small molecule targeting amyloid…
Built specifically for APOE4 carriersNCT03131453
A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
This trial tested CNP520, a drug designed to reduce amyloid buildup in the brain, against a placebo in cognitively normal older adults at elevated risk for…
Open to carriers, but ARIA risk elevatedNCT03887455
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
This Phase 3 trial tests lecanemab, an intravenous and subcutaneous antibody drug, against placebo in people with early Alzheimer's disease — either mild…
APOE4 carriers explicitly welcomedNCT04468659
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
This Phase 3 trial is testing lecanemab, an anti-amyloid antibody drug, in people who are cognitively normal but have early amyloid buildup in their brains —…
APOE4 enrolled, response may differNCT00348140
Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease
This Phase 3 trial tested rosiglitazone, a diabetes drug, as an add-on to standard Alzheimer's medications like Aricept in people with mild to moderate…
Amyloid-focused, drug did not succeedNCT02008357
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
This Phase 3 trial tested solanezumab, an antibody drug given by IV infusion, in cognitively normal older adults who already had amyloid buildup in their…
Open to carriers, not 4-specificNCT02245737
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
This trial tested lanabecestat, a BACE inhibitor drug designed to reduce amyloid production in the brain, against a placebo over two years in people with early…
Heart trial, genotype not relevantNCT02884206
Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction
This Phase 3 trial tested whether LCZ696 (sacubitril/valsartan, sold as Entresto) protects cognitive function better than valsartan alone in people with a…
Discontinued trial, not APOE4-specificNCT02972658
A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia
This Phase 3 trial tested lanabecestat, a BACE inhibitor drug designed to reduce amyloid production in the brain, in people with early Alzheimer's dementia. It…
Open to carriers, not 4-specificNCT03108846
Escitalopram for Agitation in Alzheimer's Disease
This Phase 3 trial is testing whether escitalopram, a common antidepressant, can safely reduce agitation in people who already have Alzheimer's dementia. Phase…
Open to carriers, not 4-specificNCT03848312
Preventing Alzheimer's With Cognitive Training
This Phase 3 trial is testing whether a specific type of computerized brain training — called speed of processing training — can delay the onset of mild…
Not APOE4-related, movement disorder focusNCT03924414
Trial of Parkinson's And Zoledronic Acid
This trial is testing whether a single IV infusion of zoledronic acid, a bone-strengthening drug already approved for osteoporosis, can reduce fractures in…
Open to carriers, genotype not trackedNCT04171323
The Active Mind Trial: An Adaptive Randomized Trial to Improve Function and Delay Dementia
This trial is testing different combinations of computerized brain exercises to see which combination best helps older adults with mild cognitive impairment…
Open to carriers, not 4-specificNCT04262206
Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
PREVENTABLE is a large Phase 4 trial testing whether atorvastatin 40 mg — a common cholesterol-lowering statin — can reduce the combined risk of death,…
High ARIA risk for carriersNCT04437511
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
This Phase 3 trial tested donanemab, an anti-amyloid antibody drug, against placebo in people with early Alzheimer's disease. Researchers measured how well it…
Open to carriers, not 4-specificNCT05511363
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
This Phase 3 trial is testing KarXT, an oral drug, to see whether it prevents the return of psychosis symptoms — hallucinations and delusions — in people who…
Late-stage dementia care, genotype not relevantNCT05644262
Life's End Benefits of cannaBidiol and tetrahYdrocannabinol
This Phase 2 trial is testing whether a liquid oral combination of THC and CBD (the two main active compounds in cannabis) can reduce agitation in people with…
Open to carriers, genotype not consideredNCT05896332
rTMS in Older Adults With MCI and AUD
This trial is testing whether repetitive transcranial magnetic stimulation (rTMS) — a non-invasive brain stimulation device — can simultaneously reduce heavy…
Late-stage AD only, genotype not relevantNCT05980949
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
This trial is testing whether KarXT, a drug targeting certain brain receptors, is safe to take for up to a year in people who already have Alzheimer's-related…
Open to carriers, not 4-specificNCT05992831
Transcranial Magnetic Stimulation for MCI
This trial is testing a non-invasive brain stimulation technique called accelerated TMS (transcranial magnetic stimulation) in people who have both mild…
Open to carriers, not 4-specificNCT06223360
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
This trial is testing benfotiamine — a fat-soluble form of vitamin B1 — at two different doses against a placebo, in people who already have early Alzheimer's…
Open to carriers, not 4-specificNCT06799429
Train Your Brain Fitness SC: An Exercise Intervention for People With Cognitive Impairments
This trial is testing a twice-weekly exercise and coaching program for adults with mild to moderate cognitive impairment. One group meets in person, the other…
Open to carriers, not 4-specificNCT07011732
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
This trial is testing two drug combinations — KarXT (xanomeline plus trospium) and KarX-EC — to see whether they reduce agitation in people with confirmed…
Anti-amyloid drug — carriers verify eligibilityNCT07170150
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
This trial is testing trontinemab, an anti-amyloid antibody drug given by injection, against a placebo in people with early Alzheimer's — from mild cognitive…
Gateway study, genotype not specifiedNCT07177352
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
This is not a treatment trial. It is a pre-screening study run by Roche to figure out who might qualify for their future Alzheimer's disease trials.…
Non-drug trial, genotype not specifiedNCT07526740
Brain Stimulation and Cognitive Training for MCI
This trial is testing whether combining a type of non-invasive brain stimulation called intermittent theta burst stimulation (iTBS) with computerized cognitive…
Open to carriers, genotype not trackedNCT07638046
Mindful Walking Neural Correlates of Executive Function in SC Older Adults at Risk of Dementias
This trial is testing whether mindful walking, which pairs gentle strolling with mindfulness practice, does more to support brain function and thinking skills…

Copy a forum-ready post

Keep exploring

An APOE4 carrier’s guide to clinical trials →Browse all hubs →

Educational, not medical advice. Trial decisions belong between you and your physician.